Several studies have suggested that elevated serum levels of CA15.3 and CEA at the time of diagnosis are significantly associated with tumor size, axillary node metastasis and advanced stage in breast cancer patients [6; 8–10]. This evidence concerns the gene CEACAM5 and breast carcinoma.